The accurate evaluation of axillary lymph node status in lymph node positive breast cancer patients after neoadjuvant therapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033505

Enrollment

Unknown

Registered

2020-06-03

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Lymph node pathology

Index test:Targeted&#32

lymph&#32

node&#32

biopsy,&#32

TLNB

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients aged >= 18 and <= 70 years; 2. Female; 3. Patients with a score of 0 or 1 in the Eastern Cooperative Oncology Group (ECoG); 4. Patients with ct0-4cn1-2m0.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients; 2. Patients with severe cardiopulmonary dysfunction and abnormal coagulation mechanism can not tolerate NT, puncture and operation.

Design outcomes

Primary

Measure	Time frame
False negative rate;Accuracy;Detection rate;Sensitivity;	—

Secondary

Measure	Time frame
Expression of microRNAs in tumor tissue before and after neoadjuvant therapy;Expression of microRNAs in axillary lymph nodes before and after neoadjuvant therapy;Expression of exosomal microRNAs in plasma before and after neoadjuvant therapy;The model in predicting nodal pathological complete response (pCR);	—

Countries

China

Contacts

Public ContactBin Hua

Beijing Hospital

huabin3250@bjhmoh.cn+86 13693294508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026